aTyr Pharma, Inc.(US:ATYR) Globenewswireยท2025-11-08 20:33Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of aTyr Pharma, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3][5]. - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage completely, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4].